DAMIAN Assets: dexfadrostat phosphate (DP13) & DP14
Primary Aldosterone (PA) is an endocrine disorder with known cause and known negative outcomes, but no targeted therapy.
Dexfadrostat phosphate (DP13), a first-in-class investigational medicine from DAMIAN, directly inhibits aldosterone synthase, the cause of the hormonal imbalance in PA. Following the successful completion of a Phase I study in healthy volunteers, dexfadrostat phosphate was tested in a recently completed Phase II study that evaluated its safety and efficacy in patients with PA.
Dexfadrostat phosphate has the potential to medically control PA and to provide a cost-effective alternative to surgical intervention. The complementary diagnostic tracer, DP14, is in the research phase of development.